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INTRODUCTION 
Mesenchymal stem-cell is a pluripotent 
cells that can be differentiated into many kinds of 
cells (1) and have abilities to differentiated into 
mature cell, secreted cytokines, and releasing 
many kinds of protein functioned in body body 
regulation (2). However, the therapeutic effect of 
stem cell arise from their secreted factor such as 
growth factors, cytokines, chemokines, and 
metabolits which acts as biologic regulator in the 
autocrine and paracrine body function (3). 
Secreted factors of mesenchymal stem cells 
known as secretome or mesenchimal stem cell 
conditioned medium (MSC-CM) have therapeutic 
effect for antiapoptosis, angiogenic, 
immunomodulatoric, and chemoattraactive 
activity (4). Mesenchymal stem cell conditioned 
medium used as the replacement agent for cell 
therapy because it contains no cells and save for 
used in different individual (5). 
Type 1 diabetes mellitus (DMT1) is a 
disorder characterized by destruction of the 
insulin-producing pancreatic β-cell that 
progressively leads to insulin deﬁciency and 
resultant hyperglycemia. Insulin deﬁciency can 
lead to progressive metabolic derangement, with 
worsening hyperglycemia, ketoacidosis, 
starvation, and death (6). Glucagon is a hormone 
produced by pancreatic α cells. Glucagon releases 
by the pancreas to raise the concentration of 
glucose in the bloodstream when the 
concentration of glucose in the bloodstream too 
low (7). Glucagon worked in opposite with insulin, 
which lowers the extracellular glucose level, while 
insulin works to increase the extracellular glucose 
level (8). 
 The aim of this study was to investigate 
the role of MSC-CM on the structural and 
functional regeneration of pancreatic α and β cells 
in Wistar rat (Rattus norvegicus) induced with 
type 1 diabetes mellitus. The datas in this study 
will completes the information about the effect of 
MSC-CM on pancreatic cells regeneration, which 
has been presented in previous study (9). 
MATERIALS AND METHODS 
Thirty male Wistar rats (Rattus 
norvegicus) were used in this study. Rats divided 
into two groups: control and MSC-CM treated 
group (injection of 0.05 ml/kg b.w. MSC-CM).  
Rats induced to DMT1 by single dose 125 
mg/kg b.w. alloxan monohydrate intramuscular 
injection. Rats in MSC-CM treated group received 
MSC-CM injection at week-1, 2, 3, and 4. Three rats 
from each groups were euthanized every week 
respectively. Pancreas was collected for 
histological examination. Pancreas divided into 3 
region: gastric, splenic, and duodenal regions. 
Histologic preparation was done by paraffin 
method. Pancreatic tissue then stained with 
immunohistochemistry method for insulin and 
glucagon. Results were analyzed descriptively. 
 
RESULT AND DISCUSSION 
Histological observation detected the 
change in profile of pancreatic α and β-cells 
balance in the islets of treated group after first 
injection of MSC-CM. The number and size of the 
islets increased each week after injection in 
insulin immunohistochemistry stain. The presence 
of insulin-positive cells increased every weeks for 
four weeks in all region of pancreas (splenic, 
gastric,a nd duodenal). The number of glucagon-
positive cells were increased on first week of MSC-
CM administration and decreased dramatically at 
second week until the fourth week after the 
administration of MSC-CM in all region (splenic, 
gastric, and duodenal) of pancreas. 
In the control group, there was no insulin-
positive cells detected, while glucagon was 
detected in small number. In week-1 to 2 after 
injection, the number of insulin-positive cells and 
glucagon-positive cells were increasing. In week-3 
to 4 after MSC-CM injection, the number of 
insulin-positive cells keep increasing, however the 
glucagon-positive cells were decreasing.  
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Figure 1. Immunopositive cells of insulin (A-E) 
and glucagon (F-J) pointed by black arrow in the 
islet of Langerhans, splenic region of pancreas. 
There was no insulin-positive cell detected in 
control (A). Note the size of islet and number of 
insulin-positive cell was increasing from 1 (B), 2 
(C), 3 (D) and reach maksimum size at 4 (E) weeks 
after MSC-CM injection. The glucagon-positive 
cells detected in small number in control (F), and 
the number increasing at 1 (G) and 2 (H) weeks 
after MSC-CM injection, but decreasing at 3 (I) and 
4 (J) weeks after MSC-CM injection. (Insulin and 
glucagon immunohistochemistry staining, 500x 
magnification). 
 
We managed to make rats model of type 1 
diabetes mellitus with single dose alloxan 
injection (9), indicated by the absence of insulin-
positive cells detected in control group.  The 
presence of small islets and insulin-positive cells 
started to show in week-1 after MSC-CM injection, 
and gradualy increased until week-4. This 
indicated that the administration of MSC-CM 
successfully increasing the regeneration of β-cells 
that produce insulin in the pancreas. The 
increased number of insulin-positive cells then 
affected the α-cells that produces glucagon. In 
week-1 to 2 after MSC-CM injection, the glucagon-
positive cells detected with high number 
compared to insulin-positive cells, but they 
gradually decreasing in week-3 to 4 (Figure 1).  
The body regulation can maintain the balance of α 
and β cells in pancreatic islets. The balance of 
insulin and glucagon production then maintain the 
glucose concentration in bloodstream. According 
to the previously study about diabetes mellitus 
(10), the changes in number of insulin-positive 
cells in pancreatic islets were matching with 
glucose concentration in the bloodstream. 
Our MSC-CM has been studied before can 
accelerate the regeneration of burn wound skin 
(11), skin wound (12), diabetes mellitus type 1 
(9), and diabetes mellitus type 2 (10). This study, 
however, aims to know the effect of MSC-CM 
injection in DMT1, in relation with regeneration of 
both α and β-cells in all regions of pancreas 
(gastric, duodenal, and splenic). Factors contained 
in MSC-CM have a possibility to help the body to 
regenerate the damaged in pancreas in relation to 
DMT1. Injection of MSC-CM in DMT1 rats can 
increasing the regeneration of the β-cells which is 
destructed in DMT1 case.  
 
CONCLUSION 
Mesenchymal stem cell conditioned 
medium injection once a week for 4 weeks can 
improve the regeneration of pancreatic β-cells as 
indicated by the increasing of insulin-positive 
cells, followed by the decreasing of pancreatic α-
cells as indicated by the small number of glucagon 
positive cells in rats with DMT1.  
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